button bars forest bayes pooled summary circles
 
deaths (OS)

metastatic (mCRPC) - 1st line (L1) castration-resistant prostate cancer (CRPC) metastatic (mCRPC) - 1st line (L1)

versus placebo
ipilimumab alone vs. placebo 2 0.96 [0.74; 1.24], 2 RCTs, I2=71%
inconclusive result

metastatic, hormone-sensitive prostate cancer metastatic, hormone-sensitive prostate cancer

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons